The Stanley Medical Research Institute

Summaries of Approved Treatment Trial Grants from the March 2005 Submissions

 

Zubin Bhagwagar, MD, et al.

Yale University School of Medicine

New Haven, CT

A 6-week, double-blind, placebo-controlled, adjunctive study of levetiracetam in 45 patients with bipolar depression.

 

Raz Gross, MD, et al.

Columbia University

New York, NY

A 12-week, randomized, double-blind, placebo-controlled, parallel group study of the

therapeutic effects of add-on treatment with simvastatin in 80 patients with schizophrenia.

 

James P. Kelleher, MD, et al.

St. Vincent’s Hospital Westchester

Harrison, NY

A 12-week, randomized, double-blind, placebo-controlled study of high-dose pramipexole added to risperidone for the treatment of 40 patients with schizophrenia.

 

Vladimir Lerner, MD, PhD, et al.

Ben-Gurion University of the Negev

Beersheba, Israel

A 6-week, open-label study of adjunctive bexarotene in 25 patients with schizophrenia.

 

F. Markus Leweke, MD

University of Cologne

Cologne, Germany

A 31-day, double-blind, randomized, placebo-controlled cross-over study of cannabidiol as monotherapy in 16 patients with schizophrenia.

 

Sarah H. Lisanby, MD, et al.

New York State Psychiatric Institute       

New York, NY

A 32-week, randomized, double-blind, controlled investigation of Magnetic Seizure Therapy (MST) as treatment for 75 patients with bipolar I and II depression.

 

Roger S. McIntyre, MD, et al.

University Health Network

Toronto, Ontario, Canada

An 8-week, randomized, double-blind, controlled study of intranasal insulin in 60 euthymic patients with bipolar disorder.

Anil K. Malhotra, MD, et al.

The Zucker Hillside Hospitals

Glen Oaks, NY

An 8-week, randomized, double-blind, placebo-controlled study of adjunctive pramipexole in 50 euthymic bipolar I disorder patients.

 

A. John Rush, MD, et al.                                             

UT Southwestern Medical Center                                    

Dallas, TX                                             

A 32-week, randomized, double-blind, controlled investigation of Magnetic Seizure Therapy (MST) as treatment for 75 patients with bipolar I and II depression.

 

Adam J. Savitz, MD, PhD, et al.

Weill Medical College of Cornell University

White Plains, NY

A 16-week, double-blind, placebo-controlled study of adjunctive pregnenolone in the treatment of negative symptoms in 100 patients with schizophrenia.